Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
暂无分享,去创建一个
W. Choi | J. Winter | M. Piris | T. McDonnell | G. Bhagat | Y. Zu | K. Young | Z. Xu-Monette | L. Medeiros | K. Richards | M. Møller | J. Huh | G. Manyam | Li Zhang | C. Visco | E. Hsi | M. Ponzoni | A. Ferreri | J. V. van Krieken | Yong Li | R. Miranda | K. Dybkaer | A. Chiu | R. Sun | B. Dabaja | A. Tzankov | A. Orazi | Xiaoying Zhao | Yi Xia | M. Tu | B. Parsons | Xiao-xiao Wang | L. Yin
[1] W. Choi,et al. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy , 2015, Modern Pathology.
[2] K. Young,et al. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management , 2015, Oncotarget.
[3] W. Choi,et al. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions , 2015, Modern Pathology.
[4] L. Medeiros,et al. MYC Cytogenetic Status Correlates With Expression and Has Prognostic Significance in Patients With MYC/BCL2 Protein Double-positive Diffuse Large B-cell Lymphoma , 2015, The American journal of surgical pathology.
[5] W. Choi,et al. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma , 2015, Oncotarget.
[6] K. Young,et al. Genetic lesions in diffuse large B-cell lymphomas. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Y. Oki,et al. A clinician's guide to double hit lymphomas , 2015, British journal of haematology.
[8] A. Rosenwald,et al. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma , 2015, Leukemia.
[9] L. Staudt,et al. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. , 2015, Blood.
[10] W. Choi,et al. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma , 2015, Oncotarget.
[11] A. Rosenwald,et al. Diffuse Large B-cell Lymphomas of Immunoblastic Type Are a Major Reservoir for MYC-IGH Translocations , 2015, The American journal of surgical pathology.
[12] W. Chan,et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B‐cell lymphoma treated with rituximab , 2014, British journal of haematology.
[13] R. Spang,et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma , 2014, Haematologica.
[14] A. Melnick,et al. Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation. , 2014, Blood.
[15] A. Rosenwald,et al. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. , 2013, Blood.
[16] W. Choi,et al. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.
[17] J. Briones,et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy , 2013, Haematologica.
[18] W. Choi,et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.
[19] Joonsoo Kang,et al. SMAD regulatory networks construct a balanced immune system , 2013, Immunology.
[20] W. Choi,et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. , 2013, Blood.
[21] C. Thieblemont,et al. MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future? , 2013, Blood.
[22] A. Rosenwald,et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. , 2013, Blood.
[23] W. Choi,et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study , 2013, Haematologica.
[24] C. Leslie,et al. BCL6 positively regulates AID and germinal center gene expression via repression of miR-155 , 2012, The Journal of experimental medicine.
[25] Francis A. Cucinotta,et al. Novel Smad proteins localize to IR-induced double-strand breaks: interplay between TGFβ and ATM pathways , 2012, Nucleic acids research.
[26] W. Choi,et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. , 2012, Blood.
[27] Ash A. Alizadeh,et al. Role of Smad Proteins in Resistance to BMP-Induced Growth Inhibition in B-Cell Lymphoma , 2012, PloS one.
[28] M. Pfreundschuh. Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] L. Staudt,et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Charles Y. Lin,et al. Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.
[31] D. Green,et al. c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells , 2012, Cell.
[32] K. Rajewsky,et al. MYC is essential for the formation and maintenance of germinal centers , 2012, Nature Immunology.
[33] K. Dybkær,et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2012, Leukemia.
[34] M. Benekli,et al. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B‐cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab , 2012, Cancer.
[35] P. L. Bergsagel,et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. , 2012, Blood.
[36] K. Young,et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] G. Brede,et al. Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC , 2012, Leukemia.
[38] S. Monti,et al. Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas , 2012, PloS one.
[39] K. Young,et al. High Levels of Nuclear MYC Protein Predict the Presence of MYC Rearrangement in Diffuse Large B-cell Lymphoma , 2012, The American journal of surgical pathology.
[40] A. Ariza,et al. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas , 2011, Histopathology.
[41] S. Orkin,et al. MicroRNA-21 Limits In Vivo Immune Response-Mediated Activation of the IL-12/IFN-γ Pathway, Th1 Polarization, and the Severity of Delayed-Type Hypersensitivity , 2011, The Journal of Immunology.
[42] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[43] J. Läuter,et al. MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4 , 2011, Oncogene.
[44] D. Pisano,et al. MicroRNA signatures in B-cell lymphomas , 2010, Blood Cancer Journal.
[45] S. Barrans,et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] D. Felsher. MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. , 2010, Genes & cancer.
[47] R. Gascoyne,et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.
[48] R. Gascoyne,et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.
[49] E. Obermann,et al. Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment , 2009, Journal of Clinical Pathology.
[50] L. Mazzucchelli,et al. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. , 2009, Human pathology.
[51] Michel C Nussenzweig,et al. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. , 2008, Immunity.
[52] F. Jardin,et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas , 2007, Leukemia.
[53] E. Schuuring,et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] Richard Simon,et al. Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.
[55] R. Spang,et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.
[56] W. Choi,et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP , 2014, Modern Pathology.
[57] G. Brede,et al. Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC , 2012, Leukemia.
[58] M. Henriksson,et al. MYC in oncogenesis and as a target for cancer therapies. , 2010, Advances in cancer research.